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Introduction
Pancreatic b-cells have the specialized function of regulating glu-
cose homeostasis by synthesizing and secreting the hormone insu-
lin.1 Newly synthesized insulin is not immediately functional—it 
must be folded into its proper three-dimensional structure. The 
endoplasmic reticulum (ER) has an essential role in the processing 
and assembly of insulin, with its complex of chaperones, such as 
immunoglobulin heavy chain-binding protein (BiP) and foldases, 
such as protein disulfide isomerase (PDI).
The sensitive folding environment of the ER can be disrupted 
by physiological processes, such as post-prandial insulin biosyn-
thesis which places a heavy load on the ER, as well as a patho-
logical exposure to viruses, toxins, cytokines and mutant protein 
expression.2,3 ER stress occurs when the ER exceeds its folding 
capacity with such disruptions, leading to an overall dysregula-
tion of protein homeostasis, reflected as reduced maintenance 
of the quality and quantity of protein and an accumulation of 
unfolded/misfolded proteins that cannot be processed through 
the secretory pathway. This stress elicits an ER-to-nucleus sig-
naling cascade, the Unfolded Protein Response (UPR), which 
mitigates stress in three distinct manners: (1) enhancement of 
folding activity through increased chaperone/foldase expres-
sion, (2) reduction of ER workload through general translational 
attenuation and (3) clearance of protein aggregation and residual 
unfolded proteins through ER-associated protein degradation 
(ERAD). When the UPR does not adequately reduce stress and 
return the cell to a state of protein homeostasis, the cell under-
goes apoptosis.4
b-cell apoptosis has recently been shown not only to be a com-
ponent of type 1 diabetes, but also type 2 diabetes.5 In type 1 
diabetes, b-cells are selectively destroyed by a combination of 
autoimmune and inflammatory processes leading to an absolute 
insulin deficiency, whereas in type 2 diabetes, resistance to insulin 
in peripheral tissues accompanied by a reduction in b-cell mass 
leads to relative insulin deficiency.6,7 Recent data suggests that 
ER stress contributes to b-cell death, autoimmunity and insulin 
resistance in the pathogenesis of diabetes. This review outlines 
the delicate balance of b-cell protein homeostasis and the mecha-
nisms of ER stress-mediated b-cell dysfunction and death.
The ER Stress Signaling Triad
The UPR has three master transducers which serve to mitigate 
stress: inositol requiring 1 (IRE1), PKR-like kinase (PERK), and 
activating transcription factor 6 (ATF6). The ER chaperone BiP 
binds to each of these to maintain them in an inactive state until 
ER stress is present (i.e., unfolded and misfolded proteins accu-
mulate in the ER lumen) (Fig. 1).
IRE1, is a type 1 ER transmembrane kinase that has endori-
bonuclease activity.8 Mammalian cells have two isoforms, 
IRE1α and IRE1b, which both have functions as sensors of the 
UPR. IRE1α is ubiquitously expressed, while the b isoform is 
uniquely expressed in the epithelial cells of the gastrointestinal 
tract.9 When unfolded or misfolded proteins accumulate in the 
ER, IRE1 dimerizes and undergoes trans-autophosphorylation 
to become active. Activation of its kinase domain leads to activa-
tion of its endoribonuclease function, whereby the mRNA of the 
transcription factor X-box protein binding 1 (XBP1) is uncon-
ventionally spliced. Spliced XBP1 translocates to the nucleus 
where it upregulates a variety of UPR target genes encoding 
ERAD components, as well as foldases such as PDI.10
PERK, also a type 1 ER transmembrane kinase, senses stress in 
its N-terminal luminal domain. When released from BiP, PERK 
dimerizes and undergoes trans-autophosphorylation. Activated 
PERK, directly phosphorylates the α subunit of eukaryotic ini-
tiation factor 2 (eIF2α), its only identified target.11 This in turn 
inhibits general protein synthesis, while preferentially increasing 
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In pancreatic b-cells, the endoplasmic reticulum (ER) is the 
crucial site for insulin biosynthesis, as this is where the protein-
folding machinery for secretory proteins is localized. Perturba-
tions to ER function of the b-cell, such as a high demand for in-
sulin secretion, can lead to an imbalance in protein homeostasis 
and lead to ER stress. This stress can be mitigated by an adap-
tive, cellular response, the Unfolded Protein Response (UPR). 
UPR activation is vital to the survival of b-cells, as these cells 
represent one of the most susceptible tissues for ER stress, 
due to their highly secretory function. However, in some cases, 
this response is not sufficient to relieve stress, leading to apop-
tosis and contributing to the pathogenesis of diabetes. Recent 
evidence shows that ER stress plays a significant role in both 
type 1 and type 2 diabetes. In this review, we outline the mech-
anisms of ER stress-mediated b-cell death and focus on the role 
of ER stress in various forms of diabetes, particularly a genetic 
form of diabetes called Wolfram Syndrome.
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the biosynthesis and translation of the precursor proinsulin in the 
ER, in which there is approximately a 10-fold increase in synthesis 
from a low-glucose (<3 mM) to higher glucose concentrations.18,19 
Preproinsulin is synthesized in the cytoplasm and co-translationally 
translocated into the ER. Preproinsulin’s signal peptide is cleaved 
in the ER to generate proinsulin, which then undergoes precise 
folding in the lumen of the ER, where three disulphide bonds are 
formed. Once proinsulin is properly folded, it is transported to the 
Golgi and packaged into secretory granules, where it is processed 
to yield mature insulin.20
b-cells, due to their heavy engagement in insulin secretion,21 
have been found to be very sensitive to disruptions in ER homeosta-
sis.22 This is reflected in the fact that these cells have a highly devel-
oped ER and a high expression of ER stress transducer proteins 
such as IRE1α, PERK, total XBP1, GRP94 and BiP.23-27 Thus, 
while b-cells have a robust ER signaling system, they are sensitive 
to disruptions in a system that is already at capacity. These cells are 
exposed to frequent energy fluctuations (i.e., intermittent changes 
in blood glucose levels), and thus require precise and proper fold-
ing of proinsulin to respond to such changes. Thus, any imbalance 
between the load of insulin translation placed on the ER and the 
ER folding capacity will lead to ER stress and a disruption in pro-
tein homeostasis in these cells.
The IRE1-XBP1 signaling pathway is important for ER expan-
sion,28 and the IRE1α isoform is highly expressed in the pan-
creas.29 b-cells have been shown to have a baseline phosphorylation 
of IRE1α, illustrating the high activity of the UPR in these cells. 
Suppression of IRE1 activity inhibits proinsulin biosynthesis, while 
activation enhances insulin biosynthesis in an XPB1-independent 
manner.27 While the downstream targets of this unique IRE1 
pathway have yet to be identified, it is known that the ER-resident 
oxidoreductase, endoplasmic oxidoreductin 1 (ERO1α) is upregu-
lated. ERO1α, is an activator of PDI, which is critical in catalyz-
ing the formation of disulphide bonds during protein folding in 
the ER.30 Thus, IRE1 activation may enhance insulin biosynthesis 
through the upregulation of ERO1α which in turn is responsible 
for the vital formation of the three disulphide bonds in prosinsulin 
through PDI activation.
PERK is also highly expressed in islets.24 PERK activation 
(i.e., phosphorylation) negatively regulates insulin biosynthesis.31 
In PERK null mouse islets, high glucose treatment-induced insulin 
biosynthesis was enhanced compared to control littermate islets.24 
In b-cell-specific PERK null mice, a connection has been made 
between the expression of PERK and b-cell development and pro-
liferation.32 PERK mutations are also the cause of a genetic form 
of diabetes called Wolcott-Rallison syndrome.33 Thus, the IRE1 
pathway (positive regulator) and PERK pathway (negative regula-
tor) work together to precisely regulate insulin output, again high-
lighting the importance of the UPR in the b-cell.
Recently, it has been demonstrated that ATF6 may also have 
a function in regulating insulin. Under ER stress, ATF6 is acti-
vated, leading to a decrease in insulin gene expression.34 This 
suggests that ATF6 may have dual functions: positive regulation 
of chaperones and negative regulation of insulin promoter activ-
ity. The involvement of the UPR triad (i.e., IRE1, PERK and 
ATF6) in b-cell proteostasis and insulin biosynthesis illustrates 
translation of UPR target mRNAs, such as activating transcription 
factor 4 (ATF4).12
ATF6, on the other hand, is a type II ER transmembrane tran-
scription factor, which is released from the ER membrane when 
ER stress is present. It then transits to the Golgi where it is cleaved 
by S1 and S2 proteases, a process called regulated intramembrane 
proteolysis (RIP).13 The processed form of ATF6 translocates to 
the nucleus where it upregulates UPR genes primarily involved in 
protein folding, such as BiP.14
It is of much interest that there is extensive crosstalk between 
the three UPR pathways. For example, IRE1 null cells are still able 
to induce chaperones in response to stress,15 while a loss of ATF6α 
(one of the two ATF6 isoforms), leads to diminished activation of 
ERAD components which were originally thought to be IRE1-
dependent.16 Additionally, there is convergence of the ATF6α and 
PERK pathways, in which there is a mutual control of a subset 
of targets such as C/BEP-homologous protein (CHOP), BiP, and 
protein kinase inhibitor of 58 kDa (p58IPK).17 These types of cross-
talks were probably evolved by high eukaryotes to enhance survival 
during times of severe ER stress. The extent of the overlap between 
pathways and feedback loops could interestingly be dependent on 
cell type, with highly secretory cells, such as pancreatic b-cells, 
illustrating a greater communication between pathways.
Protein Homeostasis 
in the b-Cell
Insulin is secreted by the b-cell in response to acute hyperglycemia 
which occurs post-prandially. This secretory response stimulates 
Figure 1. The ER stress signaling triad. There are three master 
transducers of the UPR: PERK, IRE1 and ATF6 which mitigate ER stress 
through: translational control, protein refolding and protein degradation.
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mechanism against ER stress-mediated apoptotic outcomes. 
However, because of the constant demands of insulin biosynthe-
sis, this has rendered the b-cell dependent on a highly efficient 
UPR. Recent findings show that b-cells are highly susceptible 
to ER stress-mediated apoptosis and this can be a cause of 
diabetes.3,51,52
Wolfram Syndrome: A Model of ER  
Stress-Mediated b-Cell Death
Current evidence suggests that ER stress is one of the molecular 
mechanisms of b-cell dysfunction contributing to the pathogen-
esis of diabetes.41,45,53 The relationship of ER stress and diabetes 
can clearly be seen in a rare, autosomal recessive form of juvenile 
diabetes, Wolfram syndrome.
The first report of this disease was documented in 1938 when 
Wolfram and Wagener analyzed eight siblings, four of which had 
a combination of juvenile diabetes and optical atrophy.54 This 
disease has been characterized as having four cardinal compo-
nents: diabetes insipidus, diabetes mellitus, optic atrophy and 
deafness, of which only diabetes mellitus and optical atrophy 
are required to make a diagnosis.55-58 Diabetes mellitus typically 
becomes symptomatic in the first decade of life, with a mean age 
of 6, while optic atrophy follows in the second decade (mean 
age of 12)59,60 (Fig. 3). Of the other symptoms, 73% of patients 
develop diabetes insipidus, 62% develop sensorineural deafness, 
58% develop renal tract complications, and 62% develop neu-
rological defects.59 A high percentage of patients also present 
the extensive crosstalk in the UPR network which precisely regu-
lates protein secretion.
HypERactivation of the UPR
There are two protein quality control outputs of the UPR: 
homeostatic and apoptotic. The goal of the UPR is to restore 
protein homeostasis, however, this may involve apoptosis to 
ensure that highly stressed cells do not produce damaged (i.e., 
misfolded) secretory proteins. Indeed, ER stress can be classified 
into two groups: physiological and pathological.35 Physiological 
stress occurs when there is a high demand for protein load. This 
is acute stress that is readily mitigated by the UPR. One example 
of this is acute post-prandial ER stress in the b-cell—there is 
a high demand for insulin biosynthesis following food intake 
which increases the folding load of the ER. This stress is actually 
favorable to the b-cell.27
When ER stress is severe or prolonged such that it cannot be 
resolved by the UPR, cell death occurs by apoptosis.36 This pro-
longed stress can be attributed to an insufficient UPR response, or 
hyperactivation of a component of the UPR (i.e., the UPR is not 
properly regulated). There are at least three pathways involved in 
ER stress-dependent apoptosis which culminate in the activation 
of the effector cysteine protease, caspase-3: (1) transcriptional 
activation of CHOP which represses Bcl-2,37 (2) activation of the 
Jun N-terminal kinase (JNK) by IRE1-dependent recruitment of 
TNF-receptor-associated factor 2 (TRAF2)38 and (3) activation 
of caspase-12 (caspase-4 in humans)39,40 (Fig. 2).
Physiological ER stress in the b-cell is beneficial and leads to 
the highly-regulated activation of insulin biosynthesis.27 This 
is attributable to acute hyperglycemia. This physiological stress 
can also be referred to as Stimulus-Coupling Adaptation to ER 
Folding (SCAEF). In this state, the downstream apoptotic fac-
tors of the UPR are not activated. However, exposure of these 
cells to chronic, prolonged hyperglycemia induces pathological 
ER stress which impairs ER function. This leads to b-cell dys-
function and eventually cell death because this pathological stress 
leads to hyperactivation of the UPR. An example of this can be 
seen when b-cells are treated with an inhibitor of eIF2α dephos-
phorylation, salubrinal.41 Persistent activation of the PERK-
eIF2α pathway is deleterious to these cells, most likely due to 
the inhibition of general translation. Hyperactivation of IRE1, as 
measured by its chronic phosphorylation, also leads to cell death 
via the JNK pathway42 and the degradation of mRNAs encod-
ing key stress signaling regulators, such as chaperones.43 Thus, 
hyperactivation of any of the UPR triad pathways is detrimental, 
even the ATF6 pathway which controls the expression of the pro-
apoptotic CHOP transcription factor.14,44 In addition to treat-
ment of b-cells with chronic high glucose, there are other causes 
of pathological ER stress in the cells: exposure to long-chain free 
fatty acids (e.g., palmitate),45,46 hyperinsulinemia which occurs 
in the pre-diabetic stage,47 glucose deprivation,48 islet amyloid 
polypeptide (IAPP) expression49 and exposure to inflammatory 
cytokines such as IL-1b and IFNγ.50
One may consider that through the evolution of the b-cell, 
there should have been the development of a robust defense 
Figure 2. Apoptotic signaling from the UPR. When ER stress cannot 
be resolved by the UPR, ER stress-dependent apoptosis occurs. There 
are three UPR apoptotic pathways which culminate in the cleavage of 
caspase-3 leading to apoptosis: (1) CHOP induction by the ATF6 and 
PERK pathways, (2) activation of the ER-resident caspase, caspase-12, 
and (3) activation of JNK by IRE1-dependent recruitment of the adaptor 
protein, TRAF2.
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disease has led to the recent discovery of another locus for this 
disease, WFS2/Miner1/CISD2, which accounts for only a frac-
tion of Wolfram syndrome cases.76-78
WFS1 is a 100 kDa glycosylated protein that is localized to 
the ER membrame.79 Its N-terminal is cytoplasmic, while its 
C-terminal is located in the ER lumen. The C-terminal of WFS1 
is highly conserved in the mouse, rat and human. N-glycosylation 
is its only predicted post-translational modification and it is pro-
jected to have nine transmembrane domains.80 There is evidence 
which suggests that WFS1 may function as a calcium channel; 
ectopic expression of WFS1 produces an increase in calcium con-
centration in the cytosol and exhibits cation-selective channel 
activities in the ER membrane.81 This suggests that WFS1 may 
function in ER calcium homeostasis. WFS1 may also regulate 
ion homeostasis of the canalicular reticulum.69 Hence, inactiva-
tion or suppression of WFS1 may cause an imbalance in ER cal-
cium homeostasis.
While ubiquitously expressed, WFS1 is highly expressed in 
the pancreas.65 Although Wolfram syndrome patients are gener-
ally not obese, nor do they have insulitis, postmortem studies 
reveal a selective loss of b-cells in their pancreatic islets.82 In line 
with this, WFS1 is not only highly expressed in b-cells, but is 
localized to these cells in the pancreas, with no detectable expres-
sion in the various other pancreatic cell types.83
While it was known that the loss of b-cells in patients is not 
auto-immune related, the cause of cell death has been elusive 
until recently. WFS1 has been shown to be a component of IRE1 
and PERK signaling and is important in the maintenance of ER 
homeostasis, particularly in b-cells.83 It has also been reported that 
glucose-induced cytosolic calcium production is lower in the islets 
of WFS1 knockout mice as compared to controls.84 Suppression of 
WFS1 leads to high levels of ER stress in b-cells, suggesting that 
WFS1 protects b-cells against ER stress and, conversely, chronic 
ER stress is caused by a loss-of-function of WFS1 protein.83-86 
Together, these findings suggest that a lack of functional WFS1 
causes abnormal calcium homeostasis in the ER, elicits ER stress, 
and triggers apoptosis in pancreatic b-cells. This suggests that 
Wolfram syndrome can be attributed to chronic, unresolved ER 
stress in the b-cell.
The precise function of WFS1 in ER stress signaling has 
remained somewhat elusive. However, there is several lines of evi-
dence which suggest that WFS1 may be a multi-functional protein. 
For example, it was reported that the C-terminal and transmem-
brane domains of WFS1 interact with the Na+/K+ ATPase b1 
subunit. WFS1 mutations thus disrupt this interaction which is 
speculated to decrease α1 and b1 sodium pump subunit expres-
sion in b-cells leading to cell dysfunction.87 The question remains 
whether this interaction is a result of ER stress and is it primary 
or secondary to the pathology of Wolfram syndrome. In addition, 
WFS1 can bind the Ca2+/CaM complex, which suggests that WFS1 
may modulate the actions of Ca2+ as an intracelleular second mes-
senger.88 Impairment of binding of this complex may also cause 
a loss-of-function of WFS1. There is also preliminary evidence 
that WFS1 regulates a key transcription factor of the UPR, ATF6, 
through the ubiquitin-proteasome pathway. Higher expression of 
WFS1 in b-cells, prevents hyperactivation of ER stress signaling 
with urinary tract abnormalities and neuropsychiatric impair-
ment,61 while powdered cataract and retinopathy can also be seen 
in a fraction of these patients60,61 (Fig. 3). Mortality occurs in 
approximately 65% of patients before the age of 35,59 primarily 
caused by central respiratory and renal failure, as well as brain 
stem atrophy.62 While generally considered a rare disease in most 
countries, for example in the UK the prevalence is 1/770,000,59 
with a carrier frequency of 1/354,63 some countries like Japan and 
Lebanon have higher incidences.61,64
The nuclear gene responsible for this syndrome which spans 
33.4 kb of genomic DNA was identified by two separate groups 
in 1998 and named WFS1.65,66 To date, there are over 130 dis-
tinct mutations in WFS1 identified in patients.67-73 While there 
has been no descript mutational hotspot noted, most are located 
in the region which encodes the transmembrane and C-terminal 
domain of the protein, exon 8.67-70 A majority of patients are com-
pound heterozygotes for two mutations, most of which have one 
mutation that alters the C-terminal tail.70 Even mutations of the 
last seven amino acids of the C-terminal leads to a full disease 
phenotype, suggesting that this region may be important to the 
function of WFS1.74 In a survey of patient mutations, 35% were 
missense, 25% nonsense, 21% frameshift, 13% inframe dele-
tions/insertions and 3% splice-site.75 It is challenging to make 
conclusive genotype-phenotype relationships, although severely 
inactivating mutations, for example a premature stop codon, 
seem to elicit more severe symptoms than mildly inactivating 
ones, such as missense mutations, and mutations outside of exon 
8 typically present with a more mild phenotype.60,63 WFS1 muta-
tions in patients with Wolfram syndrome thus lead to a loss-of-
function of WFS1. It must be noted that the heterogeneity of this 
Figure 3. Symptom progression in Wolfram syndrome. Genetic muta-
tions in WFS1 cause Wolfram syndrome which is characterized by the 
presence of diabetes mellitus (including the selective loss of pancreatic 
beta cells) in the first decade and optic atrophy in the second decade 
after birth. There are several other auxiliary symptoms which occur 
at the later stages of the disease including diabetes insipidus and other 
neurological disorders.
www.landesbioscience.com Islets 5
as OASIS, which regulates the signaling of the UPR specifically in 
astrocytes.100 CREBH has also been identified as a hepatocyte-spe-
cific UPR transducer.101 Together, the current research on WFS1 
demonstrates that indeed there is a link between ER stress and the 
pathogenesis of various forms of diabetes: genetic, type 1 and type 
2. Thus, WFS1 may be an important target for diabetes preven-
tion and/or therapy. Currently, a patient registry has been initiated 
by Dr. Alan Permutt’s group at Washington University to better 
define the natural history of this disease and find further links 
between ER stress and common forms of diabetes.
Type 1 and Type 2 Diabetes  
and the ER Stress Connection
Genetic forms of diabetes, such as Wolfram syndrome, are just the 
tip of the iceberg when it comes to linking ER stress with the meta-
bolic syndrome. There is recent evidence which links type 1 dia-
betes and ER dysfunction. The production of pro-inflammatory 
cytokines by phagocytes, such as monocytes and macropages, plays 
a key role in the pathogenesis of this disease.102,103 This includes the 
production of TNFα, IL-12, IL-1b and IFNγ.104 These cytokines 
have be shown to decrease ER calcium and cause severe ER stress 
and ER stress-mediated apoptosis in b-cells.22,41,45,105-107 In addi-
tion, IFNγ and IL-1b in b-cells induce the production of nitric 
oxide (NO). This in turn leads to b-cell failure and apoptosis, 
thus NO also plays an important role in the pathogenesis of type 
1 diabetes.108 There is evidence that this NO-induced b-cell apop-
tosis is mediated by ER stress signaling.109 NO production leads 
to a reduction of ER calcium levels through the attenuation of the 
sarcoendoplasmic reticulum Ca2+ ATPase2b (SERCA2b), causing 
severe ER stress and induction of pro-apoptotic genes106,109,110 (Fig. 
4). It is also thought that b-cells that undergo apoptosis due to 
unresolved ER stress can be a source of “neo-autoantigens”—the 
dendritic cells in the islets which engulf these cells containing mis-
folded/unfolded proteins can stimulate the maturation of b-cell-
reactive killer T cells which can add further insult by destroying 
any remaining islets.90
There is a further connection which links ER stress and the 
UPR with type 2 diabetes. Reduction of b-cell mass is a contrib-
uting component of the pathogenesis of this form of the disease.5 
Insulin resistance is a primary feature which leads to hyperinsu-
linemia in the b-cell. This high insulin production overwhelms the 
ER folding capacity and leads to severe, chronic hyperactivation 
of the UPR, inducing b-cell apoptosis. This has been seen with 
chronic activation of IRE1 during prolonged periods of insulin 
biosynthesis which leads to activation of the IRE1-JNK pro-apop-
totic signaling pathway.38 CHOP and glycogen synthase kinase 3 
(GSK3b) may also promote the progression of type 2 diabetes via 
ER stress-mediated b-cell death.111,112 Evidence which supports this 
ER connection includes the data which shows the ER density and 
volume are over two-fold higher in human diabetic b-cells than 
non-diabetic b-cells and diabetic islets cultured in high glucose 
demonstrate an induction of BiP and spliced XBP1, which was not 
noted in non-diabetic counterparts.113 There is also a deeper link 
between the insulin resistance feature of type 2 diabetes and ER 
stress. Glucoliptoxicity (i.e., the exposure of the b-cell to chronic 
in these cells which are particularly sensitive to disruption of ER 
homeostasis and dysregulation of the UPR. Thus, WFS1 has a 
role in protecting b-cells from premature death by acting as an ER 
stress signaling suppressor.
Interestingly, WFS1 may also have a role in insulin biosynthesis 
and secretion. WFS1 expression is induced during glucose-induced 
insulin secretion.27,83 This data, along with the localization of 
WFS1 to the b-cell, suggests that WFS1 is an important compo-
nent of proinsulin folding and processing in the ER of the b-cell. 
The role of WFS1 as a regulator of the ATF6 branch of the UPR 
may also be related to its role in regulating insulin biosynthesis 
and/or secretion, demonstrating the multi-functional aspect of this 
protein. Indeed, activation of ATF6 by ER stress has been shown to 
decrease insulin gene expression.34 ATF6 polymorphisms and hap-
lotypes are also associated with impaired glucose homeostasis and 
type 2 diabetes.89 Thus, this raises the possibility that the interac-
tion between WFS1 and ATF6 not only functions as a method 
to regulate the UPR, but also insulin biosynthesis: by restricting 
ATF6 activation, WFS1 prevents ATF6-mediated suppression of 
insulin gene expression.
Studying rare diseases, such as Wolfram syndrome, can help 
lead to answers to more common diseases, because there is a single 
genetic defect which can allow researchers to focus on the function 
of a gene or protein that is often involved in common diseases. 
Indeed, a link can be made between Wolfram syndrome and com-
mon forms of diabetes in which loss of b-cell mass via apoptosis 
also occurs.5,90 For example, it has been shown in a Japanese study 
that the WFS1 allele variants R456H, H611R and I720V signifi-
cantly correlate with type 1 diabetes.91 There is also a link between 
Wolfram syndrome and type 2 diabetes. In type 2 diabetes, 
peripheral resistance to insulin action leads to hyperinsulinemia. 
This overwhelms the b-cell ER and activates ER stress signaling 
pathways.92 This chronic stress may lead to b-cell apoptosis in 
patients that are genetically susceptible to ER stress (i.e., they have 
an insufficient/defective UPR). In line with this, recent candidate-
gene approaches and genome-wide association studies confirmed 
with WFS1 a type 2 diabetes susceptibility region.93-95 Studies have 
also suggested that the WFS1 risk allele may be associated with 
impaired b-cell function and the progressive loss of insulin secre-
tion may predispose carriers of the WFS1 variant to develop type 2 
diabetes.96,97 Recently, the WFS1 risk variant, rs10010131, has been 
shown to specifically impair GLP-1-induced first phase and second 
phase insulin secretion.98 It has been suggested that this impaired 
response to GLP-1 decreases post-prandial insulin secretion and 
may influence b-cell growth and differentiation.99
The question that one may pose is: why are b-cells so sensitive to 
WFS1 mutations? Firstly, it has been demonstrated that WFS1 may 
directly play a role in the primary function of the b-cell, insulin 
biosynthesis. However, more research needs to be done to confirm 
this. Another theory is that there exists WFS1-like molecules in 
other professional secretory cells and that WFS1 confers specific-
ity on the b-cell. While WFS1 is expressed in other cell types, 
it is highly expressed in the b-cell, therefore, mutations will pri-
marily affect these cells. In line with this, the first symptom of 
Wolfram syndrome is diabetes. This could be defined as a cell-type 
specific ER stress response. There are other examples of this, such 
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